Personalized Medicine

Left- vs Right-Sided Colon Cancers

Videos - Colon Cancer

The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response [ Read More ]

Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy

Charles Bankhead

June 2017, Vol 8, No 3 - Gynecologic Cancers

National Harbor, MD—Patients with relapsed high-grade ovarian cancer with BRCA mutation derived the greatest benefit from the poly ADP-­ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting. [ Read More ]

Letermovir Prophylaxis After Transplant for CMV

Wayne Kuznar

June 2017, Vol 8, No 3 - Emerging Therapies

Orlando, FL—Prophylaxis with letermovir beginning after hematopoietic-­cell transplantation (HCT) and lasting through 100 days reduced the risk for clinically significant cytomegalovirus (CMV) infection. Furthermore, letermovir was associated with lower all-cause mortality compared with placebo, reported Francisco M. Marty, MD, Associate Professor of Medicine, Harvard Medical School, Boston, at the 2017 BMT Tandem Meetings. [ Read More ]

PV-10 Therapy Shows Promise for Hepatic Tumors

Walter Alexander

June 2017, Vol 8, No 3 - Emerging Therapies

Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium. [ Read More ]

Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer

Phoebe Starr

June 2017, Vol 8, No 3 - Breast Cancer

Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizu­mab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified. [ Read More ]

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

Wayne Kuznar

June 2017, Vol 8, No 3 - Immunotherapy

Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-­related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]